Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar-Apr;36(2):801-805.
doi: 10.21873/invivo.12766.

Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement

Carsten Nieder  1   2 , Astrid Dalhaug  3 , Bård Mannsåker  3
Affiliations

Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement

Carsten Nieder et al. In Vivo. 2022 Mar-Apr.

Abstract

Background/aim: This study was designed to evaluate the prognostic impact of the previously validated LabBM score (serum lactate dehydrogenase, C-reactive protein, albumin, hemoglobin, platelets) in a new setting, namely patients with a limited number of brain metastases, arbitrarily defined as max. 4 brain lesions, from common tumor types such as lung and breast cancer. A total of 5 metastatic lesions overall were allowed to comply with current definitions of oligometastatic cancer.

Patients and methods: For this retrospective single-institution analysis, 101 patients were identified from a previously described, prospectively maintained database.

Results: Twenty-one patients (21%) had extracranial metastases. Non-small cell and small cell lung cancer were the prevailing tumor types (78%). Forty-nine patients (49%) had normal blood test results (LabBM score 0 points). Their median survival (23 months) was significantly longer than that of patients with higher LabBM score. In multivariate analysis, LabBM score, performance status and single brain metastasis were associated with significantly better survival. Limited extracranial metastases did not impair prognosis. Patients with LabBM score 0 had a 5-year survival rate of 27% after surgery (n=24) and 39% after stereotactic radiotherapy (n=13), respectively (p=0.3).

Conclusion: Blood biomarkers can be regarded as surrogate of the metastatic burden in the body, which is not always detectable by imaging methods. In contrast to circulating tumor cells and other emerging markers, the LabBM score is inexpensive. Patients with LabBM score >0 had a 2.8-fold increased risk of death. The score might be helpful in predicting survival improvement provided by ablative local treatment of oligometastases.

Keywords: C-reactive protein; Stereotactic radiotherapy; brain metastases; lactate dehydrogenase; oligometastases; prognostic factors; whole-brain radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. Actuarial overall survival stratified by LabBM score, log-rank test, p=0.001.
See this image and copyright information in PMC

References

    1. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25. doi: 10.1038/nrurol.2016.175. - DOI - PMC - PubMed
    1. Nieder C, Tollåli T, Reigstad A, Pawinski A, Haukland E, Dalhaug A. Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers. Med Princ Pract. 2014;23(6):526–531. doi: 10.1159/000365634. - DOI - PMC - PubMed
    1. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, Congedo MT, Gomez DR, Wright GM, Melloni G, Milano MT, Sole CV, De Pas TM, Carter DL, Warner AJ, Rodrigues GB. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–355. doi: 10.1016/j.cllc.2014.04.003. - DOI - PubMed
    1. Kobayashi N, Abe T, Noda SE, Kumazaki YU, Hirai R, Igari M, Aoshika T, Saito S, Ryuno Y, Kato S. Stereotactic body radiotherapy for pulmonary oligometastasis from colorectal cancer. In Vivo. 2020;34(5):2991–2996. doi: 10.21873/invivo.12130. - DOI - PMC - PubMed
    1. Chen H, Louie AV, Higginson DS, Palma DA, Colaco R, Sahgal A. Stereotactic radiosurgery and stereotactic body radiotherapy in the management of oligometastatic disease. Clin Oncol (R Coll Radiol) 2020;32(11):713–727. doi: 10.1016/j.clon.2020.06.018. - DOI - PubMed